Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
1.
Oncogene ; 37(5): 616-626, 2018 02 01.
Article in English | MEDLINE | ID: mdl-28991228

ABSTRACT

Ossifying fibroma (OF) is a rare benign tumor of the craniofacial bones that can reach considerable and disfiguring dimensions if left untreated. Although the clinicopathological characteristics of OF are well established, the underlying etiology has remained largely unknown. Our work indicates that Men1-a tumor suppressor gene responsible of Multiple endocrine neoplasia type 1-is critical for OF formation and shows that mice with targeted disruption of Men1 in osteoblasts (Men1Runx2Cre) develop multifocal OF in the mandible with a 100% penetrance. Using lineage-tracing analysis, we demonstrate that loss of Men1 arrests stromal osteoprogenitors in OF at the osterix-positive pre-osteoblastic differentiation stage. Analysis of Men1-lacking stromal spindle cells isolated from OF (OF-derived MSCs (OFMSCs)) revealed a downregulation of the cyclin-dependent kinase (CDK) inhibitor Cdkn1a, consistent with an increased proliferation rate. Intriguingly, the re-expression of Men1 in Men1-deficient OFMSCs restored Cdkn1a expression and abrogated cellular proliferation supporting the tumor-suppressive role of Men1 in OF. Although our work presents the first evidence of Men1 in OF development, it further provides the first genetic mouse model of OF that can be used to better understand the molecular pathogenesis of these benign tumors and to potentially develop novel treatment strategies.


Subject(s)
Cell Differentiation/genetics , Fibroma, Ossifying/genetics , Osteoblasts/pathology , Osteogenesis/genetics , Proto-Oncogene Proteins/genetics , Animals , Cell Proliferation/genetics , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Disease Models, Animal , Down-Regulation , Fibroma, Ossifying/diagnostic imaging , Fibroma, Ossifying/pathology , Humans , Male , Mandible/cytology , Mandible/pathology , Mice , Mice, Transgenic , Multiple Endocrine Neoplasia Type 1/genetics , Osteoblasts/metabolism , Primary Cell Culture , Sequence Deletion , Tumor Cells, Cultured , X-Ray Microtomography
2.
Gynecol Obstet Fertil ; 38(11): 672-6, 2010 Nov.
Article in French | MEDLINE | ID: mdl-20965770

ABSTRACT

Repetitive moles are rare. They are either sporadic or familial, with or without consanguinity. Some of them can be explained by a NLRP7 mutation, which causes genomic parental imprinting alteration, with a preferential paternal phenotypic expression. Currently, no effective therapeutic solution has been developed. Among the 1687 patients declared to the French Trophoblastic Disease Reference Center, 13 presented at least two hydatidiform moles, thus less than 1% of the patients. A mutation of the NLRP7 gene was shown in six of 12 tested patients (50%) among whom three presented a homozygous mutation and three a heterozygous mutation. For an affected patient, type of mole can indifferently be a complete hydatidiform mole or a partial hydatidiform mole. We describe these cases and compare them to those already published.


Subject(s)
Hydatidiform Mole/epidemiology , Hydatidiform Mole/genetics , Uterine Neoplasms/epidemiology , Uterine Neoplasms/genetics , Adaptor Proteins, Signal Transducing/genetics , Female , Heterozygote , Homozygote , Humans , Mutation , Pregnancy
4.
Gynecol Obstet Fertil ; 35(3): 205-15, 2007 Mar.
Article in French | MEDLINE | ID: mdl-17336125

ABSTRACT

OBJECTIVES: The aim of this study was both to analyse if gestational trophoblastic neoplasia (GTN) registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon (France) were managed according to the FIGO criteria for diagnosis of GTN and if chemotherapy was adapted to the 2000 FIGO prognostic scoring system. PATIENTS AND METHODS: Retrospective, descriptive analysis of 167 GTN registered to GTC of Lyon between 1999 and 2005. RESULTS: On the one hand, 66% of women (104/158) had a diagnosis of GTN according to FIGO criteria. One third (n=54) of the patients therefore had a premature or erroneous diagnosis of a tumor, when the treatment started. No supporting element of this premature diagnosis has been found out for 26 patients. The identification of lung and vaginal metastasis and histological diagnosis of invasive mole appeared as the most mentioned inappropriate criteria for diagnosis. On the other hand, chemotherapy was adapted to 2000 FIGO scoring in 91, 5% of cases. Twelve low risk GTN were treated with polychemotherapy and two high risk GTN were treated with monochemotherapy. Moreover 29% of the patients received a non adequate treatment due to deviations from the recommended protocol. DISCUSSION AND CONCLUSION: Non respect of FIGO criteria for the diagnosis of GTN can lead to erroneous diagnosis of tumors. Identification of lung or vaginal metastasis or diagnosis of invasive mole should not automatically justify the diagnosis of gestational trophoblastic neoplasia if the decrease in HCG occurs properly. Respect of FIGO criteria for the diagnosis of GTN and adaptation of chemotherapy to 2000 FIGO scoring are necessary to avoid inadequate treatment of gestational trophoblastic neoplasia.


Subject(s)
Antineoplastic Agents/therapeutic use , Gestational Trophoblastic Disease/diagnosis , Gestational Trophoblastic Disease/drug therapy , Uterine Neoplasms/diagnosis , Uterine Neoplasms/drug therapy , Adult , Diagnosis, Differential , Female , France , Gestational Trophoblastic Disease/pathology , Humans , Neoplasm Staging , Pregnancy , Prognosis , Retrospective Studies , Treatment Outcome , Uterine Neoplasms/pathology
5.
Br J Cancer ; 96(5): 738-43, 2007 Mar 12.
Article in English | MEDLINE | ID: mdl-17311015

ABSTRACT

We evaluated a 'see and treat' procedure involving screening, colposcopy, biopsy and cryotherapy by trained nurses in one-visit in field clinics in a cervical screening study in South India for its acceptability, safety and effectiveness in curing cervical intraepithelial neoplasia (CIN). Women positive on visual inspection with acetic acid (VIA) were advised colposcopy, directed biopsies and cryotherapy if they had colposcopic impression of CIN in one visit by nurses in field clinics supervised by a doctor. Side effects and complications were assessed and cure rates were evaluated with VIA, colposcopy and biopsy if colposcopic abnormalities were suspected. Cure was defined as no clinical or histological evidence of CIN at > or =6 months from treatment. Of the 2513 women offered 'see and treat' procedure, 1879 (74.8%) accepted. Of the 1397 women with histologically proved CIN treated with cryotherapy, 1026 reported for follow-up evaluation. Cure rates were 81.4% (752 out of 924) for women with CIN 1; 71.4% (55 out of 77) for CIN 2 and 68.0% (17 out of 25) for CIN 3. Minor side effects and complications were documented in less than 3% of women. 'See and treat' with cryotherapy by nurses under medical supervision is acceptable, safe and effective for cervical cancer prevention in low-resource settings.


Subject(s)
Cryosurgery , Mass Screening , Nurses , Public Health/trends , Uterine Cervical Dysplasia/surgery , Uterine Cervical Neoplasms/surgery , Adult , Colposcopy , Female , Humans , India , Middle Aged , Treatment Outcome
6.
Oncogene ; 26(26): 3857-67, 2007 May 31.
Article in English | MEDLINE | ID: mdl-17160013

ABSTRACT

The DNA strand break-binding molecule, poly(ADP-ribose) polymerase-1 (PARP-1), plays a role in DNA repair, chromosomal stability, transcription and cell death. Accumulating evidence suggests that dysfunction of PARP-1 contributes to tumorigenesis. Here, we report that PARP-1 deficiency causes mammary carcinoma formation in female mice, and that the introduction of Trp53 mutations accelerates the onset and shortens the latency of mammary tumorigenesis. We show that PARP-1 deficiency results in chromosomal aneuploidy and centrosome amplification, which are substantiated by the inactivation of Trp53 in primary mammary epithelial (PME) cells. In addition, PARP-1 deficiency compromises p53 activation and impairs BRCA1 recruitment to the sites of DNA damage in PME cells. PARP-1 complementation partly rescues the defective DNA damage response mediated by p53 and BRCA1. The present study thus identifies a role of PARP-1 in suppressing mammary tumorigenesis in vivo and suggests that dysfunction of PARP-1 may be a risk factor for breast cancer in humans.


Subject(s)
Cell Transformation, Neoplastic/metabolism , Mammary Neoplasms, Experimental/enzymology , Poly(ADP-ribose) Polymerases/metabolism , Animals , BRCA1 Protein/metabolism , Blotting, Western , Chromosome Aberrations , Female , Fluorescent Antibody Technique , Loss of Heterozygosity , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/pathology , Mice , Poly (ADP-Ribose) Polymerase-1 , Tumor Suppressor Protein p53/genetics
7.
Oncogene ; 26(17): 2518-24, 2007 Apr 12.
Article in English | MEDLINE | ID: mdl-17043645

ABSTRACT

In human post-natal somatic cells, low global levels of DNA methylation have been associated with the hypomethylation of several repetitive elements, a feature that has been proposed to be a surrogate epigenetic marker. These data, mainly derived from the analysis of cancer cells, suggest a potential association between loss of cell-growth control and altered differentiation with hypomethylation of repetitive sequences. Partial hydatidiform moles (PHMs) can be used as an alternative model for investigating this association in a non-tumorigenic context. This gestational disease is characterized by abnormal overgrowth and differentiation of the placenta and spontaneous abortion. Here, we comprehensively analyse the DNA methylation of these trophoblastic tissues in both PHM and normal placenta at global and sequence-specific levels. Analysis of the global 5-methylcytosine content and immunohistochemistry indicate that PHM and normal placenta have identical global levels of DNA methylation. In contrast, bisulfite genomic sequencing shows that, whereas Alu, NBL2 and satellite 2 repetitive elements are equally methylated, LINE-1 sequences are hypermethylated in PHM tissues ( approximately 2-fold relative to normal placenta). Interestingly, altered demethylation is also found in triploid diandric embryos that originate from dispermic fertilization of an oocyte, a common event responsible for most PHMs. In conclusion, alterations of DNA methylation do not seem to be randomly distributed in PHM, as several repeated elements remain unaltered, whereas LINE-1 sequences are hypermethylated. In addition, our findings suggest that the hypomethylation of repetitive elements in cancer is directly linked to the neoplasic process and not a simple consequence of loss of growth control observed in most of the cancer cells.


Subject(s)
Cell Differentiation/genetics , DNA Methylation , Long Interspersed Nucleotide Elements/physiology , Placenta/pathology , Placentation , Female , Humans , Hyperplasia , Placenta/metabolism , Pregnancy
8.
J Endocrinol ; 175(2): 307-18, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12429029

ABSTRACT

We have demonstrated and localized human GH (hGH) gene expression in surgical specimens of normal human mammary gland and in proliferative disorders of the mammary gland of increasing severity using sensitive in situ RT-PCR methodology. hGH mRNA identical to pituitary hGH mRNA was first detected by RT-PCR of RNA derived from samples of normal human mammary gland. Cellular localization of hGH gene expression in the normal mammary gland exhibited restriction to luminal epithelial and myoepithelial cells of the ducts and to scattered stromal fibroblasts. We subsequently examined the expression of the hgh gene in three progressive proliferative disorders of the human mammary gland, i.e. A benign lesion (fibroadenoma), a pre-invasive stage (intraductal carcinoma) and an invasive ductal carcinoma. hGH mRNA was readily detected in the tumoral and non-tumoral epithelial components and also in cells of the reactive stroma including fibroblasts, myofibroblastic and myoepithelial cells, inflammatory infiltrate lymphocytes and endothelial cells in areas of neovascularization. In all three proliferative disorders examined, the intensity of the cellular labeling observed in both the epithelial and stromal compartments was always stronger compared with that in adjacent normal tissue. hGH protein was also present in significantly higher concentration in extracts derived from proliferative disorders of the mammary gland compared with extracts derived from normal mammary gland. We also examined hGH gene expression in axillary lymph nodes not containing and containing metastatic mammary carcinoma. hGH gene expression was evidenced in metastatic mammary carcinoma cells and in reactive stromal cells by both in situ hybridization and in situ RT-PCR. In contrast, in lymph nodes not containing metastatic mammary carcinoma, hGH mRNA was detected only by use of in situ RT-PCR. Thus, increased expression of the hGH gene in the epithelial component and the de novo stromal expression in proliferative disorders of the mammary gland are suggestive of a pivotal role for autocrine hGH in neoplastic progression of the mammary gland.


Subject(s)
Carcinoma in Situ/genetics , Fibroadenoma/genetics , Gene Expression/genetics , Growth Hormone/genetics , Mammary Neoplasms, Animal/genetics , Breast/pathology , Breast/physiopathology , Carcinoma in Situ/pathology , Epithelium/pathology , Epithelium/physiology , Female , Humans , Lymphatic Metastasis/genetics , Neoplasm Invasiveness/genetics , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction
9.
Fertil Steril ; 75(4): 754-62, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11287031

ABSTRACT

OBJECTIVE: To test the toxicity of cryoprotectant in sheep ovarian tissue and to determine optimal conditions for freezing hemiovary cortex. DESIGN: Small follicles (<60 microm in diameter) were isolated enzymatically for viability testing. Dead and live follicles were identified by using trypan blue staining, and follicle morphology was examined histologically. SETTING: Centre hospitalo-universitaire de Biologie de la Reproduction, Hôpital Edouard Herriot, Lyon, France. ANIMAL(S): Lambs 5 to 6 months of age. INTERVENTION(S): Two-millimeter slices of hemiovarian cortex were prepared for cryoprotectant toxicity tests and freezing procedures. MAIN OUTCOME MEASURE(S): Follicular mortality and histologic structure. RESULT(S): For freezing procedures, the concentration of cryoprotectant was increased to 2 M on the basis of results of cryoprotectant toxicity tests in fresh tissues. Follicular mortality rates were 4.6% with of 2 M dimethyl sulfoxide (DMSO) and 3.8% with 2 M of propylene glycol (PROH). After freezing with semiautomatic seeding, follicular mortality rates were 8.4% (2 M of DMSO) and 12.4% (2 M of PROH). Tissue morphology was well preserved with 1.5 M of DMSO or PROH. With 1.5 M DMSO, results of the slow cooling protocol (2 degrees C/min) without seeding and the standard very slow cooling protocol (0.3 degrees C/min) were similar. CONCLUSION(S): Optimal survival of primordial follicles in the sheep was obtained by using a slow cooling protocol with semiautomatic seeding at 2 M of DMSO.


Subject(s)
Cryopreservation/methods , Cryoprotective Agents/pharmacology , Organ Preservation/methods , Ovarian Follicle/cytology , Ovary , Animals , Cell Death , Cell Survival , Culture Media , Dimethyl Sulfoxide/pharmacology , Female , Ovarian Follicle/drug effects , Ovary/cytology , Propylene Glycols/pharmacology , Sheep , Time Factors
10.
J Gynecol Obstet Biol Reprod (Paris) ; 29(6): 538-47, 2000 Oct.
Article in French | MEDLINE | ID: mdl-11084460

ABSTRACT

Gestational trophoblastic diseases include partial and complete molar pregnancies together with trophoblastic tumors, namely invasive mole, choriocarcinoma and placental site trophoblastic tumor. Important advances continue to occur in both our understanding and management of these diseases. The general guidelines we display here are intended to standardize the essential current management of trophoblastic diseases and justify the creation of a reference center in France. The goal of such a center is to optimize the treatment of patients. The center can help in drawing and interpreting the human chorionic gonadotrophin regression curve and give the multidisciplinary current recommendations to the physician in charge of the patient. The aim is to diagnose and treat as soon as possible the malignant forms of the disease as the interval between the previous pregnancy and the initiation of treatment is a major prognostic factor.


Subject(s)
Hydatidiform Mole/diagnosis , Hydatidiform Mole/therapy , Uterine Neoplasms/diagnosis , Uterine Neoplasms/therapy , Female , France , Humans , Medicine , Obstetrics , Pregnancy , Referral and Consultation , Specialization
11.
Int J Cancer ; 88(4): 519-24, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11058866

ABSTRACT

BRCA1 mutations are involved in breast and ovarian cancer predisposition in humans. The biological functions of the murine BRCA1 gene have been extensively studied but little is known about murine BRCA1 proteins. To better characterize these proteins, we have cloned the full-length murine BRCA1 cDNA and a splice variant deleted of exon 11, BRCA1-delta 11, by RT-PCR method. Three polyclonal antibodies raised against various parts of murine BRCA1 were used in our study: D16, M20 and 5MO, which were generated in our laboratory. This allowed us to analyze the expression and subcellular localization of both isoforms in murine and human cell lines by immunoblotting, immunoprecipitation, cell fractionation and immunofluorescence. Endogenous BRCA1 was detected in murine cell lines but not splice variant BRCA1-delta 11, whereas both ectopically expressed murine isoforms were detected in transfected human Bosc 23 cells. Subcellular fractionation and immunofluorescence results showed that the BRCA1 protein was mainly located in the nucleus, whereas BRCA1-delta 11 was preferentially cytoplasmic. The conservation of exon 11 splicing and the differential subcellular localization of BRCA1 and BRCA1-delta 11 in human and mouse suggest that these proteins could play distinct roles and that they could differentially act in the pathological mechanisms leading to the development of breast and ovarian cancer. The characterization of the murine BRCA1 proteins and antibodies will be useful to further study BRCA1 functions in murine models.


Subject(s)
Alternative Splicing , BRCA1 Protein/genetics , Genes, BRCA1 , Genetic Variation , Sequence Deletion , 3T3 Cells , Animals , BRCA1 Protein/analysis , Base Sequence , Cloning, Molecular , DNA Primers , Exons , Gene Library , Humans , Mice , Molecular Sequence Data , Protein Isoforms/analysis , Protein Isoforms/genetics , Reverse Transcriptase Polymerase Chain Reaction , Teratoma
12.
FASEB J ; 14(11): 1585-94, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10928993

ABSTRACT

In mammalians, demethylation of specific promoter regions often correlates with gene activation; inversely, dense methylation of CpG islands leads to gene silencing, probably mediated by methyl-CpG binding proteins. In cell lines and cancers, inhibition of tissue-specific genes and tumor suppressor genes expression seems to be related to such hypermethylation. The 5' end of the breast cancer predisposition gene BRCA1 is embedded in a large CpG island of approximately 2.7 kb in length. In human sporadic breast cancers, the down-regulation of BRCA1 does not seem to be related to BRCA1 gene alterations. Southern blot analysis and the bisulfite sequencing method indicate that the BRCA1 CpG island is regionally methylated in all human tissues analyzed and unmethylated in the gametes, suggesting a role for DNA methylation in the control of gene expression. We have therefore investigated the potential role of methyl-CpG binding proteins in the regulation of BRCA1 gene expression. In vitro, partial methylation of constructs containing this region strongly inhibits gene expression in the presence of MeCP2 protein. Moreover, in the five human cell lines analyzed, chemically induced hypomethylation is associated with BRCA1 gene activation. These data suggest that methyl-CpG binding proteins might be associated with the control of BRCA1 gene expression and that methyl-DNA binding proteins may participate in the regulation of gene expression in mammalian cells.


Subject(s)
Azacitidine/analogs & derivatives , Chromosomal Proteins, Non-Histone , CpG Islands/genetics , DNA Methylation , Gene Expression Regulation , Genes, BRCA1/genetics , Germ Cells/metabolism , Repressor Proteins , Azacitidine/pharmacology , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Line , Cervix Uteri/cytology , Cervix Uteri/drug effects , Cervix Uteri/metabolism , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Decitabine , Female , Gene Expression Regulation/drug effects , Gene Silencing/drug effects , Germ Cells/drug effects , Humans , Kidney/cytology , Kidney/drug effects , Kidney/metabolism , Male , Methyl-CpG-Binding Protein 2 , Promoter Regions, Genetic/genetics , Transcriptional Activation/drug effects , Transfection
13.
Ann Oncol ; 11(3): 355-8, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10811505

ABSTRACT

BACKGROUND: Anti oestrogenic treatment is widely used for breast cancer treatment and prevention of recurrence. Because of concomitant estrogenic effects, tamoxifen exerts carcinogenic properties on the endometrium. Although secondary endometrial cancers usually present as pure adenocarcinomas, other types of rare tumors have also been reported. PATIENTS AND METHODS: Herein we describe the clinical, pathological as well as therapeutic aspects of a new case of endometrial mesodermal mixed tumor occurring after long-term tamoxifen therapy. RESULTS: The present case occured five years after cessation of a five years tamoxifen treatment. The patient failed to respond to doxorubicin and cyclophosphamide when combined to 5-fluorouracil (5-FU), but she reached complete response when the same two drugs were used with carboplatin, suggesting the potential usefullness of platinum derivatives. CONCLUSIONS: A longer latency period might be observed for endometrial mesodermal mixed tumors as compared to adenocarcinomas and could justify a prolonged clinical and ultrasonographic follow-up of patients during and after tamoxifen treatment. When indicated, chemotherapy might require the use of platinum derivatives in this particular type of secondary tumor.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Endometrial Neoplasms/chemically induced , Mixed Tumor, Mesodermal/chemically induced , Neoplasms, Second Primary/chemically induced , Tamoxifen/adverse effects , Breast Neoplasms/drug therapy , Carboplatin/administration & dosage , Carcinogens , Endometrial Neoplasms/drug therapy , Fatal Outcome , Female , Humans , Middle Aged , Mixed Tumor, Mesodermal/drug therapy , Neoplasms, Second Primary/drug therapy , Tamoxifen/therapeutic use
14.
Gynecol Obstet Fertil ; 28(1): 44-50, 2000 Jan.
Article in French | MEDLINE | ID: mdl-10774117

ABSTRACT

OBJECTIVE: Certain HPV types have transforming properties. These oncogenic activities are related to the abilities of the viral proteins E6 and E7 to inhibit the products of two cellular tumor suppressor genes (p53 and Rb respectively). But the early steps of cervical carcinogenesis are not well known. The goal of our study was to evaluate cervical intraepithelial neoplasia (CIN) for the tumor suppressor genes p53 and pRb, the HPV status and the mitotic activity, in order to better understand the mechanism of carcinogenesis. MATERIAL AND METHODS: Twenty formalin-fixed paraffin-embedded cone biopsies were selected because they contained adjacent to normal epithelium different grades of CIN. Immunohistochemistry was performed for evaluation of PCNA, pRb and p53. Expression of these different biomarkers was assessed with the help of an image analysis system, in the different epithelial layers of the different normal and pathological cervical areas. The results were compared to normal controls. RESULTS: There is an increase of PCNA expression in normal epithelium adjacent to CIN, compared to normal controls. As tissues progress from adjacent normal epithelium to condylomatous lesion and to the different grades of CIN, PCNA expression increases (mainly in the superficial epithelial layers). For p53 and pRb, the expression is increased in the basal and parabasal layers of adjacent normal epithelium and condylomatous lesions. The observance of histologic signs of CIN is associated with a disappearance of p53 and pRB expression. CONCLUSIONS: These results indicate that the early steps of cervical carcinogenesis involve proliferative dysregulation in relation to the p53 and pRb modulatory mechanism. So expression of viral proteins of HPV is probably the earlier step of carcinogenesis in cervical carcinoma.


Subject(s)
Gene Expression , Genes, Retinoblastoma/genetics , Genes, p53/genetics , Mitosis , Uterine Cervical Dysplasia/genetics , Uterine Cervical Dysplasia/pathology , Conization , Epithelium/chemistry , Epithelium/pathology , Female , Humans , Proliferating Cell Nuclear Antigen/analysis , Uterine Cervical Dysplasia/chemistry
15.
Bone ; 26(5): 485-9, 2000 May.
Article in English | MEDLINE | ID: mdl-10773588

ABSTRACT

It has been shown that the bone loss occurring with aging in spongy bone is associated with a reduced osteoblastic bone formation and an increased volume of marrow adipose tissue. This observation suggests a relationship between cells from the osteoblastic and adipogenic lineages. The purpose of the present study was to evaluate the influence of mature adipocytes on osteoblastic proliferation and activity in a model of coculture. Human primary osteoblastic (hBOB) cells were derived from femoral bone explants collected in patients undergoing orthopedic surgery. Human stromal osteoblastic (hMSOB) cells were obtained from bone marrow samples collected by aspiration during orthopedic surgery. Extramedullary and medullary mature adipocytes (hAd) showing similar functions, except for their response to insulin, hAd were isolated from mammary adipose tissue collected in women undergoing tumorectomy. Cells were cocultured, with hAd being separated from osteoblastic cells (hBOB or hMSOB) by a porous membrane (0.4 microm). When hBOB cells were seeded on the upper side of the insert and hAd were floating on the lower side, cell contacts between the two cell types were possible through the pores of the membrane. At the end of the experiment, proliferation of the osteoblastic cells was evaluated by [(3)H]-thymidine incorporation and alkaline phosphatase (AP) activity was measured. After 20 h of coculture, proliferation of the hBOB cells was significantly decreased when compared with control hBOB (-40 +/- 6%, p < 0.05). To establish whether or not the influence of hAd on hBOB proliferation required intercellular communications, hAd and hBOB cells were cocultured far from the porous membrane. Six other independent experiments confirmed an inhibition of hBOB proliferation under both experimental conditions (p < 0.05): -35 +/- 7% with possible intercellular contacts, and -30 +/- 7% without any contact. In contrast, the proliferation of hMSOB cells was not significantly modified after coculture with hAd. In addition, the presence of hAd did not significantly modify the AP activity of hBOB (0.163 +/- 0.143 and 0.181 +/- 0.114 nmol/min per microgram of protein in controls and after coculture, respectively). No reproducible effect of hAd-conditioned medium was noted on hBOB- and hMSOB-cell proliferation or hBOB-cell activity. In conclusion, mature adipocytes induced an inhibition of hBOB-cells proliferation, probably mediated by a factor secreted by hAd. This effect may contribute to the age-related reduction of bone formation and bone loss.


Subject(s)
Adipocytes/cytology , Cell Division , Osteoblasts/cytology , Alkaline Phosphatase/metabolism , Coculture Techniques , Humans , Osteoblasts/enzymology
16.
Int J Cancer ; 85(6): 877-81, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10709111

ABSTRACT

We have investigated the endogenous expression of menin, a protein encoded by the gene mutated in multiple endocrine neoplasia type 1 (MEN1). Western blot analysis showed strong expression of menin as a 68 kDa protein in all of 7 human and primate cell lines tested. In a panel of 12 fetal human tissue extracts, 68 kDa menin was readily detected in brain cortex, kidney, pituitary, testis and thymus and weakly detected in thyroid. Reproducible bands other than 68 kDa were observed in adrenal and heart, whereas menin was undetectable in liver, lung, pancreas and skin. Analysis of synchronized HeLa cells revealed no variation in the amount or size of menin throughout the cell cycle. Protein expression was compared between lymphoblastoid cell lines from healthy controls and MEN1 patients carrying nonsense mutations on 1 allele. No truncated protein was detected in either cytoplasmic or nuclear fractions in mutation-carrying cells. The expression level and cellular location of full-length menin did not differ between cell lines derived from MEN1 patients and healthy donors. This suggests that the wild-type allele has been up-regulated in mutation-carrying cells to compensate for the loss of 1 functional allele.


Subject(s)
Multiple Endocrine Neoplasia Type 1/genetics , Neoplasm Proteins/genetics , Proto-Oncogene Proteins , Animals , Blotting, Western , Cell Cycle , Fetus , Gene Expression , Humans , Mutation , Neoplasm Proteins/metabolism , Primates , Reference Values , Tumor Cells, Cultured
17.
Oncogene ; 18(27): 4039-43, 1999 Jul 08.
Article in English | MEDLINE | ID: mdl-10435628

ABSTRACT

Germ-line alterations of BRCA1 are associated with elevated risk of breast cancer. Evidence for the involvement of Brca1 in cellular differentiation and morphogenesis has been obtained in mouse models during embryogenesis. Although the presence of well-conserved functional domains might suggest a similar function for both human and mouse genes, very few data on BRCA1 expression in human fetal tissues are available. We have, therefore, investigated the expression of BRCA1 in the mammary gland from human female fetuses aged between 15 and 33 weeks. Quantification of BRCA1 transcripts, using a competitive reverse transcriptase PCR method, indicates a progressive decrease in BRCA1 expression with increasing fetal age between the 15th and 30th week of gestation. Subsequently, the amount of BRCA1 transcripts becomes similar to that found in adult mammary gland. Analysis of BRCA1 protein revealed, in fetal samples, a 220 kDa band corresponding to the 220 kDa BRCA1 protein described in human cell lines. These later experiments confirm that the relative level of the 220 kDa BRCA1 protein is highest in the early stages of mammary gland development. The temporal patterns of BRCA1 expression in human fetuses suggest a role for BRCA1 in the morphogenesis and differentiation of the human mammary gland.


Subject(s)
Breast/embryology , Breast/metabolism , Gene Expression Regulation, Neoplastic , Genes, BRCA1 , Adult , BRCA1 Protein/biosynthesis , BRCA1 Protein/genetics , Breast/cytology , Cell Differentiation/genetics , Cell Division/genetics , Down-Regulation/genetics , Embryonic and Fetal Development/genetics , Female , Gestational Age , Humans , Pregnancy , RNA, Messenger/metabolism , Transcription, Genetic , Tumor Cells, Cultured
18.
Pathol Biol (Paris) ; 47(4): 368-74, 1999 Apr.
Article in French | MEDLINE | ID: mdl-10372407

ABSTRACT

Thrombospondin-1 and -2 are extracellular matrix proteins that are overexpressed in breast cancer tissue. Their role in breast cancer remains unknown. This article reviews the potential effects of thrombospondin-1 and -2 in breast cancer tumori genesis and metastatic dissemination.


Subject(s)
Breast Neoplasms/blood supply , Cell Adhesion Molecules/physiology , Neovascularization, Pathologic , Thrombospondin 1/physiology , Thrombospondins/physiology , Breast Neoplasms/pathology , Female , Humans
19.
Arthritis Rheum ; 42(5): 963-70, 1999 May.
Article in English | MEDLINE | ID: mdl-10323452

ABSTRACT

OBJECTIVE: To investigate the presence and role of interleukin-17 (IL-17) in rheumatoid arthritis (RA), and its regulation by antiinflammatory cytokines. METHODS: The production of IL-17 was measured in supernatants of RA, osteoarthritis (OA), and normal synovial tissue pieces cultured ex vivo. Quantification of IL-17 was performed using a specific biologic assay. IL-17 gene expression was investigated by reverse transcriptase-polymerase chain reaction (RT-PCR)-techniques. Immunohistochemistry was used to evaluate the frequency of IL-17-positive cells in synovium. The secretion of IL-17 by synovium was measured in the presence of IL-4, IL-13, and IL-10. In addition, the contributions of exogenous and endogenous IL-17 to IL-6 production by RA synovium were studied. RESULTS: Functional IL-17 was spontaneously produced by 16 of 18 RA (mean +/- SEM 41.7+/-11.4 units/ml), 2 of 12 OA (5.3+/-4.5 units/ml), and 0 of 3 normal synovial explant cultures. IL-17 messenger RNA expression was demonstrated by RT-PCR in 4 of 5 RA and 0 of 3 OA synovial samples. By immunostaining of RA synovium, IL-17-producing cells were found in the T cell-rich area. Addition of both IL-4 and IL-13 completely inhibited the production of IL-17, whereas IL-10 had no effect. Addition of exogenous IL-17 to RA synovium resulted in an increase in IL-6 production, whereas that of a blocking anti-IL-17 antibody reduced production of IL-6. CONCLUSION: The T cell cytokine IL-17 was found to be highly produced by RA, but not by OA, synovium. Its production and function were down-regulated by IL-4 and IL-13. These results indicate that IL-17 contributes to the active, proinflammatory pattern that is characteristic of RA. Through the contribution of IL-17, some Th1-like T cells appear to mediate synovial inflammation.


Subject(s)
Arthritis, Rheumatoid/etiology , Arthritis, Rheumatoid/pathology , Interleukin-17/biosynthesis , Synovial Membrane/pathology , Cytokines/metabolism , Gene Expression/drug effects , Humans , Interleukin-1/pharmacology , Interleukin-13/pharmacology , Interleukin-17/genetics , Interleukin-4/pharmacology , Interleukin-6/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Synovial Membrane/metabolism , T-Lymphocytes/metabolism
20.
Virchows Arch ; 432(3): 289-91, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9532009

ABSTRACT

We report the second case of mammary Paget's disease arising in a supernumerary nipple of a 29-year-old woman. The epithelium of the nipple was infiltrated by large cells with abundant and pale-staining cytoplasm. The nuclei had a vesicular chromatin pattern and identifiable nucleoli. The cells were strongly immunoreactive with KL1, CEA and EMA, but did not show reactivity with PS100, HMB45, or erb-B2. The pathogenesis of Paget cells is unclear. In our case, the lesion showed nearly all the clinical, histological and histochemical characteristics of Paget's disease, though without involvement of mammary gland epithelium and underlying carcinoma. The possibility of an intraepidermal origin, either by transformation from epidermal keratinocytes or by derivation from intraepidermal precursor cells, has to be considered. The differential diagnosis against Toker cell hyperplasia is also discussed.


Subject(s)
Nipples/abnormalities , Paget's Disease, Mammary/pathology , Adult , Breast Neoplasms/pathology , Carcinoma/pathology , Diagnosis, Differential , Female , Humans , Hyperplasia , Nipples/pathology , Paget's Disease, Mammary/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...